Key facts
- This page summarizes Vittal Vasista's Form 4 filing for REGENXBIO Inc. (RGNX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Mar 2024, 17:20.
Vittal Vasista - 19 Mar 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RGNX
- Reported as of
- 19 Mar 2024
- Net transaction value
- +$75,354
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2024, 17:20:42 UTC
- Prior SEC filing
- 04 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick J. Christmas as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vittal Vasista filed Form 4 for REGENXBIO Inc. (RGNX) on 21 Mar 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: +$75,354.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RGNX
transaction
Common Stock
Options Exercise
- Transaction value
- $75,354
- Shares
- +20,041
- Change %
- +8.8%
- Price
- $3.76
- Shares after
- 246,534
- Date
- 19 Mar 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RGNX
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -20,041
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,041
- Exercise price
- $3.76
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.